Table 4.
Antimicrobial activity of other compounds.
| Drug | Drug in Combination | Kind of Study | Bacterial Inhibition | Strains Tested | Refs. |
|---|---|---|---|---|---|
| Auranofin | In vitro | 0.125–0.5 mg/L | E. coli ATCC 25922, S. aureus (ATCC 25923, USA 300), S. epidermidis (ATCC 12228, ATCC 35984 (biofilm producer)), 5 MRSA | [73] | |
| Niclosamide | - | In vitro | 0.125–64 µg/mL |
S. aureus (MRSA MW2, Newman, RN4220, RN6390, USA100, USA300, USA400), S. epidermidis 9142, E. faecium E007, K. pneumoniae ATCC 77326, A. baumannii ATCC 17978, P. aeruginosa PA14, E. aerogenes EAE 2625 and 44 S. aureus clinical |
[79] |
| Niclosamide | In vitro | 0.25 µg/mL | H. pylori 60190 ATCC 49503 | [80] | |
| Niclosamide 4 µM | Colistin | In vitro | MIC values ranging from <0.03 μg/mL to 0.125 μg/mL | Reference colistin-susceptible (Col-S) A. baumannii ATCC 17978 strain, and 13 clinical colistin-resistant (Col-R) A, reference Col-S K. pneumoniae CECT 997 strain, 1 Col-S and 2 Col-R clinical K. pneumoniae strains | [81] |
| Metformin | TX-100 | In vitro | 20 mg/mL | E. faecalis ATCC 29212 | [86] |